December 9, at Hyderabad PTI Prestige BioPharma Ltd, based in Singapore, and Dr. Reddys Laboratories Ltd. announced on Thursday that they have enrolled into a binding agreement for an exclusive partnership for the supply and commercialization of the former's proposed Trastuzumab biosimilar in select Latin American and Southeast Asian countries. According to a regulatory filing from the Indian drugmaker, Prestige BioPharmas Trastuzumab HD201 is a proposed biosimilar to Roches Herceptin. Trastuzumab is a human epidermal growth factor 2 (HER2) inhibitor. It can be prescribed to treat HER2-positive breast and metastatic gastric cancer.
Prestige BioPharma Ltd, a Singapore-based company, and Dr. Reddy's Laboratories Ltd announced on Thursday that the two companies have enrolled into a binding agreement for an exclusive partnership for the supply and commercialization of the
former's proposed Trastuzumab biosimilar in select Latin American and Southeast Asian countries.
According to a regulatory filing from the Indian drugmaker, Prestige BioPharma's Trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin. It can be prescribed to treat HER2-positive breast and metastatic gastric cancer.
Trastuzumab is a human epidermal growth factor 2 inhibitor (HER2). HER2 is overexpressed in some types of cancer cells and promotes cancer cell growth. According to the company, trastuzumab works by selectively binding to HER2, halting the growth of cancer cells.
Prestige BioPharma will be in charge of ensuring the long-term commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be in charge of local registrations, marketing, and sales in the licensed territories.
"We are delighted to enact a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets," said Lisa S Park, CEO of Prestige BioPharma. Dr. Reddy is the ideal partner for commercializing our lead biosimilar in these markets. With this partnership, we hope to increase the value of our biosimilar programs in global markets." "In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need," said M V Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy's. Our collaboration with Prestige BioPharma will enable us to combine their established expertise in biosimilars with our commercial strengths and growth ambitions in these markets. This is persistent with our stated intention to develop an oncology portfolio and expand our biosimilar offerings in Emerging Markets." GDK PTI SS